

Interleukin Therapeutic Pipeline Market Review, H2 2016

Interleukin Treatment Pipeline Review H2 2016

PUNE, INDIA, October 14, 2016

/EINPresswire.com/ -- [Interleukin 17A](#) (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted pipeline therapeutics.

A blue rectangular card with white text and icons. At the top left is the "WISE GUY REPORTS" logo, which includes a stylized profile of a head with dots. Below the logo, the text reads "Norah Trent Partner Relations & Marketing Manager". There are three rows of contact information, each preceded by an icon: an envelope for email (sales@wiseguyreports.com), a telephone for phone numbers (Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)), and social media icons for LinkedIn, Twitter, and Facebook with their respective URLs. The card is set against a background of faint white squares and a large, faint profile of a head.

The report provides comprehensive information on the Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics development and features dormant and discontinued projects.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/685873-interleukin-17a-cytotoxic-t-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain

competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)
- The report reviews Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Buy 1-User PDF @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685873

| | |
|--|--|
| Table of Contents | |
| Table of Contents 2 | |
| List of Tables 5 | |
| List of Figures 5 | |
| Introduction 6 | |
| Global Markets Direct Report Coverage 6 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview 7 | |
| Therapeutics Development 8 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Stage of Development 8 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Therapy Area 9 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Indication 10 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Pipeline Products Glance 11 | |
| Late Stage Products 11 | |
| Early Stage Products 12 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Products under Development by Companies 13 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Therapeutics Assessment 15 | |
| Assessment by Monotherapy/Combination Products 15 | |
| Assessment by Mechanism of Action 16 | |
| Assessment by Route of Administration 17 | |
| Assessment by Molecule Type 19 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Companies Involved in Therapeutics Development 21 | |
| AbbVie Inc 21 | |
| Abeome Corporation 22 | |
| Affibody AB 23 | |
| Cell Medica Limited 24 | |
| Eli Lilly and Company 25 | |
| Johnson & Johnson 26 | |
| Merck KGaA 27 | |
| Novartis AG 28 | |
| Orega Biotech SAS 29 | |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) - Drug Profiles 30 | |
| ABT-122 - Drug Profile 30 | |
| Product Description 30 | |
| Mechanism Of Action 30 | |
| R&D Progress 30 | |

ABY-035 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

CNTO-6785 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

DLX-2882 - Drug Profile 35

Product Description 35

Access Report @ <https://www.wiseguyreports.com/reports/685873-interleukin-17a-cytotoxic-t-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/349342649>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.